Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)
June 24 2024 - 2:00AM
Business Wire
Seroba, an European life sciences venture capital firm
headquartered in Dublin, with offices in Paris and Milan, and Kurma
Partners, a key European Venture Capital firm financing innovation
in Healthcare and Biotechnology, from pre-seed to growth capital,
based in Paris and Munich, announced today the completion of the
second closing part of Series B financing round of Vico
Therapeutics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240623484065/en/
Vico Therapeutics B.V. is a clinical-stage genetic medicines
company developing therapies for severe neurological diseases. Its
lead program VO659 is currently in a Phase 1/2a clinical study of
patients with spinocerebellar ataxia types 3 and 1 and Huntington’s
disease, devastating neurodegenerative diseases for which there are
currently no disease-modifying treatments available.
Seroba joined the consortium of investors leading the planned
second closing of the Series B financing round of an additional
€11.5 million ($12.4 million) with participation from Kurma Growth
Opportunities Fund supporting Vico to continue to advance their
lead clinical program and further develop a portfolio of novel
antisense oligonucleotides. Existing investors include Ackermans
& van Haaren (AvH), Droia Ventures, EQT Life Sciences, Eurazeo,
Kurma Biofund, Polaris Partners and Pureos Bioventures, for a total
Series B financing round of €65.8 million ($70.7 million).
Catello Somma, Partner at Seroba, commented:
“We are extremely proud to support Vico in this financing round
and join the existing investors. The growth capital will help the
Company to bolster its clinical programs to deliver life-changing
outcomes for patients with polyQ diseases, such as SCA and
Huntington's. We are excited to partner with Vico and its
remarkable team as the Company advances its programs.”
Daniel Parera and Jean-Francois Rivassou, Partners at Kurma,
commented:
“Vico is another very nice example of a company where Kurma
Partners acted as a co-founding investor (Rémi Droller on behalf of
Kurma Biofund III alongside with EQT Life Sciences) that has
progressed into clinical development, where Kurma Growth
Opportunities Fund is able to add further support to the Company
and its experienced management team in the continuation of Vico’s
path together with existing investors.”
About Seroba.
Seroba is a European life sciences venture capital firm based in
Dublin, Paris and Milan, investing from its fourth Fund. Seroba
focuses on value creation through backing cutting-edge biotech and
medtech innovation that will transform the treatment of patients,
addressing unmet medical needs. The Seroba team has deep industry,
operational and investing experience and an extensive global
network. Seroba likes to work with entrepreneurs who share its
passion for success and with investors who share the same goal of
improving human health while driving financial returns.
Follow Seroba’s story at https://serobavc.com/
About Kurma Partners
Founded in July 2009 and based in Paris and Munich, Kurma
Partners is a key European Venture Capital firm financing
innovation in Healthcare and Biotechnology, from pre-seed to growth
capital. Kurma invests through its funds Kurma Biofund I, II and
III, Kurma Diagnostics and Kurma Diagnostics 2, and the most recent
Kurma Growth Opportunities Fund, for which this is the eighth
investment. Kurma collaborates through extensive networks of
prestigious research and academic institutes, premier cluster
organizations and hospitals connecting with established industry
players. Kurma Partners is part of the Eurazeo Group.
www.kurmapartners.com (www.eurazeo.com/en)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240623484065/en/
Contact Seroba Maud Lazare Head of Investor Relations,
Partner mlazare@serobavc.com
Contact Kurma Partners Muriel Domine
muriel.domine@kurmapartners.com